Want to see VTRS full AI Analyst Report?
VTRS Stock Chart & Stats
$14.68
>-$0.01(-0.04%)
At close: 4:00 PM EST
$14.68
>-$0.01(-0.04%)
Day’s Range― - ―
52-Week Range$8.63 - $17.53
Previous CloseN/A
Volume2.11M
Average Volume (3M)9.78M
Market Cap
$19.55B
Enterprise Value$30.86B
Total Cash (Recent Filing)$1.80B
Total Debt (Recent Filing)$14.34B
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 06, 2026EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend Yield3.99%
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,173,682,000
10 Day Avg. Volume9,246,614
30 Day Avg. Volume9,775,887
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue2.12
Enterprise Value/Gross Profit6.16
Enterprise Value/Ebitda12.03
Forecast
1Y Price Target
$17.60Price Target Upside19.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)2.46
Revenue Forecast (FY)$14.78B
Bulls Say, Bears Say
Bulls Say
Cash Generation & LiquiditySustained positive operating cash flow and a multi-billion cash war chest provide durable financial flexibility. This supports debt service, dividends, targeted M&A or capex without relying on near-term profit improvement, insulating strategy from short-term earnings volatility.
Late‑stage Pipeline & Regulatory CatalystsA concentrated set of late-stage regulatory milestones and accepted NDAs represents structural upside to revenue mix if approved. Successful approvals diversify revenues beyond commoditized generics and can sustainably improve margins through higher-value branded and complex products.
Debt Refinancing & Maturity ExtensionRefinancing near-term maturities with longer-dated euro notes reduces rollover risk and smooths the debt schedule. Improved maturity profile and demonstrated market access strengthen credit optionality and provide time to execute operational improvements.
Bears Say
Negative Trailing Net IncomePersistent negative TTM net income shows the business has not yet converted revenue and margin improvements into consistent GAAP profitability. That constrains retained earnings, weakens ROE, and limits long-term capacity to fund growth from internal profits without drawing on cash or issuing debt.
Multi‑year Revenue DriftA structural decline in revenues over several years indicates competitive loss of share or market deflation in core generics markets. That trend raises the bar for new product launches to replace lost volume and implies ongoing pressure on scale-driven margins and long-term organic growth.
Launch And Regulatory Execution RiskMaterial near-term growth assumptions rely on multiple pending approvals and successful commercial rollouts. Regulatory delays, adverse decisions, or weaker-than-expected launches would materially curtail projected revenue and margin gains, exposing the company to concentrated execution risk.
Viatris News
VTRS FAQ
What was Viatris, Inc.’s price range in the past 12 months?
Viatris, Inc. lowest stock price was $8.63 and its highest was $17.53 in the past 12 months.
What is Viatris, Inc.’s market cap?
Viatris, Inc.’s market cap is $19.55B.
When is Viatris, Inc.’s upcoming earnings report date?
Viatris, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 27 days.
How were Viatris, Inc.’s earnings last quarter?
Viatris, Inc. released its earnings results on May 07, 2026. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.502 by $0.088.
Is Viatris, Inc. overvalued?
According to Wall Street analysts Viatris, Inc.’s price is currently Undervalued.
Does Viatris, Inc. pay dividends?
Viatris, Inc. pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 3.99%. See more information on Viatris, Inc. dividends here
What is Viatris, Inc.’s EPS estimate?
Viatris, Inc.’s EPS estimate is 0.61.
How many shares outstanding does Viatris, Inc. have?
Viatris, Inc. has 1,173,682,000 shares outstanding.
What happened to Viatris, Inc.’s price movement after its last earnings report?
Viatris, Inc. reported an EPS of $0.59 in its last earnings report, beating expectations of $0.502. Following the earnings report the stock price went up 9.032%.
Which hedge fund is a major shareholder of Viatris, Inc.?
Currently, no hedge funds are holding shares in VTRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.60 (19.89% Upside)
$17.60 (19.89% Upside)
Blogger Sentiment
Bullish
VTRS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.02%
12-Months-Change
Fundamentals
Return on Equity
-1.97%
Trailing 12-Months
Asset Growth
-4.26%
Trailing 12-Months
Company Description
Viatris, Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
VTRS Company Deck
VTRS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed solid operational performance and momentum: top-line revenue growth (3%), strong adjusted EBITDA expansion (10%), sizable China acceleration (+18%), meaningful pipeline progress with multiple upcoming regulatory catalysts, and robust cash flexibility (> $2.5B). These positives were tempered by regional softness (Europe, JANZ), supply constraints in lower-margin generics/ARV, ongoing regulatory timing uncertainty, and policy risk in China. On balance, the positives (broad-based execution, margin control, late-stage pipeline momentum and financial flexibility) outweigh the lowlights.View all VTRS earnings summariesVTRS Net sales Breakdown
64.45% Brands
35.55% Generics
VTRS Stock 12 Month Forecast
Average Price Target
$17.60
▲(19.89% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Ownership Overview
0.27% Insiders
27.20% Mutual Funds
0.50% Other Institutional Investors
44.48% Public Companies and
Individual Investors